FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: Pivot Naturals

  • Home
  •  | 
  • Tag Archives: "Pivot Naturals"

Pivot Naturals LLC Awarded Temporary License to Manufacture Adult and Medicinal Use Cannabis from the California Department of Public Health

Pivot Naturals LLC Awarded Temporary License to Manufacture Adult and Medicinal Use Cannabis from the California Department of Public Health
Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) ("Pivot") is pleased to announce that it has received a Temporary License from the California Department of Public Health to manufacture adult and medicinal use cannabis-infused products in its Costa Mesa, California facility. Receipt of this license brings Pivot one step closer to production, generating revenue, and bringing its brands to the California ingestible and edible cannabis market.
Read more

Pivot Naturals LLC Receives Three Additional Notices of Allowance from USPTO

Pivot Naturals LLC Receives Three Additional Notices of Allowance from USPTO
Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) ("Pivot" or the "Company") is pleased to announce that its wholly-owned subsidiary, Pivot Naturals LLC, has received three more Notices of Allowance from the U.S. Patent and Trademark Office ("USPTO") for patent applications related to its RTIC "Ready-To-Infuse Cannabis" powderization technology
Read more

Pivot Completes C$1.64 Million Non-Brokered Private Placement

Pivot Completes C$1.64 Million Non-Brokered Private Placement
VANCOUVER, Oct. 22, 2018 /CNW/ - Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) ("Pivot" or the "Company") is pleased to announce that it has closed a non-brokered Private Placement (the "Private Placement") for a total of C$1,641,300 and has also settled C$1,500,000 of outstanding debt with the issuance of common shares and share purchase warrant. Proceeds of the Private Placement will be used for general working capital purposes, capital expenditures and patent costs.
Read more